HOOKIPA Pharma Announces Board of Directors Changes

Core Viewpoint - HOOKIPA Pharma Inc. has announced leadership changes in its Board of Directors, with Julie O'Neill appointed as Non-Executive Chair, succeeding Jan van de Winkel, who stepped down due to increased commitments as CEO of Genmab A/S, and Tim Reilly also stepping down to focus on other responsibilities [1][2]. Company Overview - HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies based on its proprietary arenavirus platform, aimed at mobilizing and amplifying targeted T cells to combat serious diseases [3]. - The company's pipeline includes investigational arenaviral immunotherapies targeting Human Papillomavirus 16-positive cancers, KRAS-mutated cancers, and other undisclosed programs, as well as efforts to develop functional cures for HBV and HIV in collaboration with Gilead [3].